Moreover, fortunately, the availability of the approved AR inhibitors (e.g., enzalutamide, bicalutamide, abiraterone acetate, and seviteronel) used to treat prostate cancer creates a chance for AR-based drug repurposing for breast cancer [10, 11]. This evidence concerns the gene AR and prostate carcinoma.